Dialyse und Nierentransplantation

Schlüsselwörter

Hämodialyse - Peritonealdialyse - Nierentransplantation - donorspezifische Antikörper - Belatacept

Keywords

hemodialysis - peritoneal dialysis - renal transplantation - donor specific antibodies - belatacept

• Literatur

• 1 Agarwall R, Sinha AD, Pappas MK et al. Hypertension in hemodialysis patients treated with atenolol or lisinopril. J Am Soc Nephrol 2014; 29: 672-681
• 2 Charpentier B, Medina Pestana JO, Del CRM et al. Long-term exposure to belatacept in recipients of extended criteria donor kidneys. Amer J Transplant 2013; 13: 2884-2891
• 3 Choi SJ, Kim EJ, Park MY et al. Does body fat mass define survival in patients starting peritoneal dialysis?. Perit Dial Int 2013; Feb 1. [Epub ahead of print]
• 4 Hoogeveen EK, Halbesma N, Rothman KJ et al. Netherlands Cooperative Study on the Adequacy of Dialysis-2 (NECOSAD) Study Group. Obesity and mortality risk among younger dialysis patients. Clin J Am Soc Nephrol 2012; 7: 280-288
• 5 Isakova T, Guiterrez OM, Chang Y et al. Phosphorus binders and survival hemodialysis. J Am Soc Nephrol 2012; 20: 388-396
• 6 Kawanishi K, Honda K, Tsukada M et al. Neutral solution low in glucose degradation products is associated with less peritoneal fibrosis and vascular sclerosis in patients receiving peritoneal dialysis. Perit Dial Int 2013; 33: 242-251
• 7 Ketteler M, Biggar PH. Use of phosphate binders in chronic kidney disease. Curr Opin Nephrol Hypertens 2013; 22: 413-420
• 8 Lachmann N, Terasaki PI, Budde K et al. Anti-human leukocyte antigen and donor-specific antibodies detected by luminex posttransplant serve as biomarkers for chronic rejection of renal allografts. Transplantation 2009; 87: 1505-1513
• 9 Lefaucheur C, Loupy A, Hill GS et al. Preexisting donor-specific HLA antibodies predict outcome in kidney transplantation. J Amer Soc Nephrol 2010; 21: 1398-1406
• 10 Lopes AA, Tong L, Thumma J et al. Phosphate binder use and mortality among hemodialyis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 2012; 60: 90-101
• 11 Loupy A, Lefaucheur C, Vernerey D et al. Complement-binding anti-HLA antibodies and kidney-allograft survival. N Engl J Med 2013; 369: 1215-1226
• 12 Maduell F, Moresco F, Pons M et al. High-efficiency postdilution online hemodiafiltration reduces all-cause mortality in hemodialysis patients. J Am Soc Nephrol 2013; 24: 487-497
• 13 Mostovaya IM, Bots ML, van den Dorpel MA et al. A randomized trial of hemodiafiltration and change in cardiovascular parameters. Clin J Am Soc Nephrol 2014; 9: 520-526
• 14 Ok E, Asci G, Toz H et al. Turkish Online Haemodiafiltration Study. Mortality and cardiovascular events in online haemodiafiltration (OL-HDF) compared with high-flux dialysis: results from the Turkish OL-HDF Study. Nephrol Dial Transplant 2013; 28: 192-202
• 15 Rostaing L, Vincenti F, Grinyo J et al. Long-term belatacept exposure maintains efficacy and safety at 5 years: results from the long-term extension of the BENEFIT study. Amer J Transplant 2013; 13: 2875-2883
• 16 Soveri I, Snyder J, Holdaas H et al. The external validation of the cardiovascular risk equation for renal transplant recipients: applications to BENEFIT and BENEFIT-EXT trials. Transplantation 2013; 95: 142-147
• 17 Tinckam KJ, Heeger PS. Transplantation: Complementing donor-specific antibody testing. Nature Rev Nephrol 2013; 9: 713-714
• 18 Torlen K, Kalanter-Zadeh K, Molnar MZ et al. Serum potassium and cause-specific mortality in a large peritoneal dialysis cohort. Clin J Am Soc Nephrol 2012; 7: 1272-1278
• 19 Wang AY, Ninomiya T, Al-Kahwa A et al. Effect of hemodiafiltration or hemofiltration compared with hemodialysis on mortality and cardiovascular disease in chronic kidney failure: a systematic review and meta-analysis of randomized trials. Am J Kidney Dis 2014; Mar 27 pii: S0272-6386